# Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer

> **NIH NIH R01** · UNIVERSITY OF SOUTHERN CALIFORNIA · 2022 · $676,023

## Abstract

Abstract
Prostate cancer (PC) afflicts more men in the U.S. than any other malignancy and is the second leading cause
of cancer death in this population. Recently, new therapies have improved survival in some men but have offered
little benefit to others. Tissue profiling has identified genes and pathways associated with resistance and
progression to advanced disease, but little is known about the dynamics of when and how such changes arise
during therapy. Such insights can only be gained through minimally invasive monitoring that allows repeated
disease profiling over time. Our multidisciplinary team has developed and tested two such minimally invasive
monitoring capabilities: The first is multi-parametric liquid biopsy: streamlined analysis of blood samples that
simultaneously measures PC-relevant cellular and molecular features from single circulating tumor cells and
matched plasma cell-free nucleic acids. The second is radiomic analysis: high-throughput extraction of
quantitative metrics to identify PC-relevant phenomic imaging features. By synergizing the strengths of the two
methods, our goal is to test the hypothesis that liquid biopsy and radiomic techniques can be applied jointly to
monitor metastatic PC noninvasively over time, culminating in new prognostic and predictive tools to guide
therapy. To maximize the impact of our findings, liquid biopsy profiling and radiomic analysis will be integrated
into Southwest Oncology (SWOG) S1802, a phase 3 prospective therapeutic trial for over 1200 men with newly
diagnosed metastatic castrate sensitive prostate cancer (mCSPC) treated with standard systemic therapy alone
or in combination with definitive treatment of the primary tumor. Notably, SWOG and the other participating
cooperative groups have reviewed and approved this proposal (see Letters of Support), and the requisite blood
samples and CT scans already are being collected as part of the active protocol. In this unique setting, we will
pursue three Specific Aims. We will: 1. Use multi-parametric liquid biopsies to monitor the evolving cellular and
molecular landscape of mCSPC during treatment in S1802; 2. Use radiomic analysis of CT scans to monitor the
evolving radiographic landscape of mCSPC during treatment in S1802; and 3. Integrate cellular, molecular, and
radiomic data to develop composite disease monitoring models predictive of PFS and OS. Importantly, liquid
biopsies and CT images will be matched within patients and analyzed at key inflection points over the course of
the trial: at diagnosis, after initiation of systemic therapy, after definitive therapy, and at disease progression. In
this way, the proposed work will illuminate when and how PC-relevant phenotypes arise during therapy, and how
they relate to clinical outcomes. In particular, we will better understand which components of the liquid biopsy –
circulating cells, plasma, or both – most accurately reflect the tumor's evolving molecular profile, which radiomic
metrics m...

## Key facts

- **NIH application ID:** 10348199
- **Project number:** 5R01CA257610-02
- **Recipient organization:** UNIVERSITY OF SOUTHERN CALIFORNIA
- **Principal Investigator:** Vinay Duddalwar
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $676,023
- **Award type:** 5
- **Project period:** 2021-02-09 → 2026-01-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10348199

## Citation

> US National Institutes of Health, RePORTER application 10348199, Integrated radiomic and liquid biopsy monitoring in SWOG S1802: A phase 3 therapeutic trial for metastatic prostate cancer (5R01CA257610-02). Retrieved via AI Analytics 2026-05-22 from https://api.ai-analytics.org/grant/nih/10348199. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*